October 27, 2005 -- Biomira reported that its vaccine provided a sizeable survival benefit to lung cancer patients; PPD received a not approvable letter for its premature ejaculation drug; Schering-Plough said its oral treatment for serious invasive fungal infections was approved in Europe; Flamel reported a successful Phase III test of its Micropump technology; and ZymoGenetics will begin a Phase III trial of its recombinant human Thrombin in patients undergoing surgery. The Centient Biotech 200™ was down 62 points at 3670, a drop of 1.67%. More details...
